Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.